Evidence map›Paper›PMID 34968728›Full record

Observational studyClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2022

Impact of SARS-CoV-2 Pandemic on Vascular Liver Diseases.

Anna Baiges, Eira Cerda, Caroline Amicone, Luis Téllez, Edilmar Alvarado-Tapias, Angela Puente, Jose Ignacio Fortea, Elba Llop, Filipa Rocha, Lara Orts and 21 more

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Management of splanchnic vein thrombosis.JHEP reports : innovation in hepatology · 2023
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 6 institutions in 2 countries.

Anna BaigesHepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases.
Eira CerdaHepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases.
Caroline AmiconeUniversité de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
Luis TéllezServicio Gastroenterología y Hepatología, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, CIBERehd, Madrid, Spain.
Edilmar Alvarado-TapiasDepartment of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, CIBERehd, Barcelona, Spain.
Angela PuenteGastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain.
Jose Ignacio ForteaGastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain.
Elba LlopGastroenterology and Hepatology Department, IDIPHISA, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain.
Filipa RochaUniversité de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
Lara OrtsHepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases.
Oliva Ros-FargasHepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases.
Pamela VizcarraHepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases.
Kamal ZekriniUniversité de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
Ould Amara LounesUniversité de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
Ghiles TouatiUniversité de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
Natalia Jiménez-EsquivelHepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases.
Maria Jose SerranoHepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases.
Angels FalgàHepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases.
Marta MagazHepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases.
Pol OlivasHepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases.
Fabian BetancourtHepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases.
Valeria Perez-CampuzanoHepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases.
Fanny TuronHepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases.
Audrey PayancéUniversité de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
Odile GoriaUniversité de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
Pierre-Emmanuel RautouUniversité de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
Virginia Hernández-GeaHepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases.
Candid VillanuevaDepartment of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, CIBERehd, Barcelona, Spain.
Agustin AlbillosServicio Gastroenterología y Hepatología, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, CIBERehd, Madrid, Spain.
Aurélie PlessierUniversité de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France. Electronic address: aurelie.plessier@aphp.fr.
Juan-Carlos García-PagánHepatic Hemodynamic Lab, IDIBAPS, CIBERehd, Universitat de Barcelona, Hospital Clínic de Barcelona, Spain, and European Reference Network (ERN) RARE-Liver, Hepatological diseases. Electronic address: jcgarcia@clinic.cat.
Hospital Clínic de Barcelona · ESInserm · FRMarqués de Valdecilla University Hospital · ESUniversidad de Alcalá · ESUniversitat Autònoma de Barcelona · ESHospital Universitario Puerta de Hierro Majadahonda · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsVascular liver diseases (VLDs) are represented mainly by portosinusoidal vascular disease (PSVD), noncirrhotic splanchnic vein thrombosis (SVT), and Budd Chiari syndrome (BCS). It is unknown whether patients with VLDs constitute a high-risk population for complications and greater coronavirus disease 2019 (COVID-19)-related mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our objective was to assess the prevalence and severity of SARS-CoV-2 infection among patients with VLDs, as well as to assess its impact on hepatic decompensation and survival.

methodsThis is an observational international study analyzing the prevalence and severity of SARS-CoV-2 infection in VLDs between March 2020 and March 2021, compared with the general population (GP). Patients from Spain (5 centers; n = 493) and France (1 center; n = 475) were included.

resultsNine hundred sixty-eight patients were included: 274 with PSVD, 539 with SVT, and 155 with BCS. Among them, 138 (14%) were infected with SARS-CoV-2: 53 with PSVD, 77 with SVT, and 8 with BCS. The prevalence of SARS-CoV-2 infection in patients with PSVD (19%) and SVT (14%) was significantly higher than in the GP (6.5%; P < .05), whereas it was very similar in patients with BCS (5%). In terms of infection severity, patients with VLDs also presented a higher need of hospital admission (14% vs 7.3%; P < .01), intensive care unit admission (2% vs 0.7%; P < .01), and mortality (4% vs 1.5%; P < .05) than the GP. Previous history of ascites (50% vs 8%; P < .05) and post-COVID-19 hepatic decompensation (50% vs 4%; P < .05) were associated with COVID-19 mortality.

conclusionsPatients with PSVD and SVT could be at higher risk of infection by SARS-CoV-2 and at higher risk of severe COVID-19 disease.

Indexed as

COVID-19Liver DiseasesVascular DiseasesHumansPandemicsSARS-CoV-2Budd Chiari SyndromeCOVID-19Portosinusoidal Vascular DiseaseSARS-CoV-2Splanchnic Vein ThrombosisVascular Liver Diseases

Identifiers

PMID34968728
PMCPMC8710430
OpenAlexW3199497673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.